Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ganglioneuroblastoma, Nodular”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Large-scale testing (Phase 3)Looking for participantsNCT06172296
What this trial is testing

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Who this might be right for
Ganglioneuroblastoma, NodularNeuroblastoma
National Cancer Institute (NCI) 478
Testing effectiveness (Phase 2)WithdrawnNCT06858501
What this trial is testing

Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Who this might be right for
GanglioneuroblastomaGanglioneuroblastoma, NodularHigh Risk Neuroblastoma
Children's Oncology Group
Large-scale testing (Phase 3)Looking for participantsNCT03126916
What this trial is testing

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Who this might be right for
GanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma
Children's Oncology Group 750
Testing effectiveness (Phase 2)Active Not RecruitingNCT04385277
What this trial is testing

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Who this might be right for
Ganglioneuroblastoma, NodularNeuroblastoma
Children's Oncology Group 41